Nystatin (Fungicidin) is a topical and oral antifungal agent with activity against many species of yeast and candida albicans, which is used largely to treat skin and oropharyngeal candidiasis.

METHODS: Hippocampal neurons were treated with Nystatin (2.5-25 µM) for 30 min and cell morphology was examined.
RESULTS: Acute incubation with different concentrations of Nystatin increased the growth cone size of hippocampal neurons. [1]
METHODS: CHO cells were treated with Nystatin (100-300 µmol/L) for 10-60 min, and cell viability was measured by MST-1 assay.
RESULTS: Cell viability studies after Nystatin application showed significant concentration- and time-dependent effects. At Nystatin concentrations equal to 100 µmol/L, the percentage of viable cells was significantly higher compared to higher concentrations. [2]

Nystatin combined with endostatin selectively enhances endostatin uptake and biodistribution in tumor blood vessels and tumor tissues rather than in normal tissues of tumor-bearing mice, ultimately leading to elevated antiangiogenic and antitumor efficacies of endostatin in vivo[3]. Liposomal Nystatin, at doses as low as 2 mg/kg of body weight/day, protects neutropenic mice against Aspergillus-induced death in a statistically significant manner at the 50-day time point compared to either the no-treatment, the saline, or the empty-liposome group[4].